ArticleFrontiers in pharmacology2024

Proteomic assessment of SKBR3/HER2+ breast cancer cellular response to Lapatinib and investigational Ipatasertib kinase inhibitors.

Arba Karcini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.